Salvia secures $60m oversubscribed Series B to advance chronic migraine implant

Salvia is developing MySalvia Therapy, a personalised neuromodulation treatment designed to reduce the frequency and intensity of migraine attacks through a minimally invasive implant approach. The company positions the therapy as an alternative for patients who remain inadequately served by current preventive treatments, particularly given high discontinuation rates reported for existing migraine medications.

The Series B round was led by Innovation Industries, with participation from Invest-NL and the EIC Fund, alongside existing investors including SHS Capital. The company states that the capital will support completion of its clinical programme and the transition to commercial readiness.

A key focus is progress of RECLAIM, Salvia’s multi-centre, double-blind, sham-controlled study in chronic migraine patients, intended to generate the clinical evidence required for regulatory approvals and adoption in routine care. In parallel, Salvia plans to advance regulatory submissions, including securing FDA market authorisation in the US and progressing approvals in Europe and Australia.

Salvia also highlights that MySalvia Therapy has received FDA Breakthrough Device designation, underlining its potential to address an important unmet need in chronic migraine. The company notes potential longer-term applicability of the technology in other headache disorders such as cluster headache, although the therapy remains under evaluation and is not yet approved for commercial use.

Read the full article here: link